Serous Ovarian Cancer Clinical Trials

16 recruitingLast updated: May 29, 2026

There are 16 actively recruiting serous ovarian cancer clinical trials across 23 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable. Top locations include Houston, Texas, United States, Oklahoma City, Oklahoma, United States, Austin, Texas, United States. Updated daily from ClinicalTrials.gov.


Serous Ovarian Cancer Trials at a Glance

16 actively recruiting trials for serous ovarian cancer are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Houston, Oklahoma City, and Austin. Lead sponsors running serous ovarian cancer studies include Astra Zeneca, AstraZeneca, and AbbVie.

Browse serous ovarian cancer trials by phase

Treatments under study

About Serous Ovarian Cancer Clinical Trials

Looking for clinical trials for Serous Ovarian Cancer? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Serous Ovarian Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Serous Ovarian Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled45 locationsNCT05005403
Recruiting
Phase 1Phase 2

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

ER+ HER2- Advanced Breast CancerHigh-grade Serous Ovarian Cancer (HGSOC)
AstraZeneca564 enrolled14 locationsNCT06188520
Recruiting
Phase 1Phase 2

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Endometrial CancerRecurrent Ovarian CancerLow Grade Serous Ovarian Cancer+3 more
Regeneron Pharmaceuticals890 enrolled52 locationsNCT03564340
Recruiting
Phase 2

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

Low Grade Serous Ovarian Cancer
Memorial Sloan Kettering Cancer Center20 enrolled8 locationsNCT06394804
Recruiting

CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer

Circulating Tumor DNAHigh Grade Serous Ovarian Cancer
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine100 enrolled1 locationNCT05027828
Recruiting
Phase 3

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Low Grade Serous Ovarian Cancer
Verastem, Inc.270 enrolled106 locationsNCT06072781
Recruiting
Phase 1

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Triple-Negative Breast CancerColorectal, CancerNon-small Cell Lung Cancer+5 more
IDEAYA Biosciences150 enrolled5 locationsNCT07503808
Recruiting
Phase 3

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer+4 more
Genelux Corporation186 enrolled31 locationsNCT05281471
Recruiting
Phase 2

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

Cervical CancerSolid TumorHigh Grade Serous Ovarian Cancer+2 more
University of Oklahoma55 enrolled4 locationsNCT05512208
Recruiting
Phase 2

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Ovarian CancerSerous Ovarian Cancer
Sarah K. Lynam MD31 enrolled1 locationNCT05113368
Recruiting
Phase 1

Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer

High Grade Serous Ovarian Cancer
Institute of Cancer Research, United Kingdom33 enrolled3 locationsNCT06976892
Recruiting

Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary

Exploring HER2 Positive Diagnostic Criteria in High-grade Serous Ovarian CancerObserving the Effectiveness of Targeted HER2 ADC Drugs
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University144 enrolled1 locationNCT06883487
Recruiting
Not Applicable

Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging

High Grade Serous Ovarian Cancer
Institut du Cancer de Montpellier - Val d'Aurelle120 enrolled1 locationNCT06084195
Recruiting

Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma

High Grade Serous Ovarian Cancer
IRCCS Azienda Ospedaliero-Universitaria di Bologna150 enrolled1 locationNCT06777082
Recruiting
Phase 2

Assessment of Efficacy of AZD2281 in Platinum Sensitive Serous Ovarian Cancer

Platinum Sensitive Serous Ovarian Cancer
Astra Zeneca250 enrolled9 locationsACTRN12609000159257